Resmed INC Form 4 insider transactions

Michael J. Farrell, Chairman and CEO and a Director of Resmed Inc, sold 4,991 shares of common stock on August 7, 2026 for $205.69 per share.

Peter C Farrell, a Director of Resmed Inc, sold 8,000 shares of common stock on August 5, 2026 for $225.00 per share.

ResMed CEO Michael Farrell executed a series of transactions involving the acquisition and disposition of company stock under a pre-arranged Rule 10b5-1 trading plan.

ResMed Inc. Chairman and CEO Michael J. Farrell reported the sale of 4,991 shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

ResMed's Global General Counsel, Michael J. Rider, reported a disposition of company stock for tax withholding purposes related to vested Restricted Stock Units.

ResMed Inc. Chairman and CEO Michael Farrell reported transactions involving company stock, including acquisitions and dispositions, executed under a pre-arranged Rule 10b5-1 trading plan.

ResMed Inc. Chief Financial Officer Brett Sandercock has officially retired from his position effective May 4, 2026.

ResMed Chairman and CEO Michael Farrell executed a Rule 10b5-1 trading plan, acquiring 4,991 shares and selling 4,991 shares.

ResMed Inc. Chief Financial Officer Brett Sandercock executed a transaction involving 1,000 shares of common stock under a pre-established Rule 10b5-1 trading plan.

ResMed Chairman Emeritus Peter C. Farrell sold 2,000 shares of common stock at $225 per share via a 10b5-1 trading plan.

ResMed Director Peter C. Farrell sold 2,000 shares of common stock for $260.22 per share under a pre-arranged 10b5-1 trading plan.

ResMed Chairman and CEO Michael J. Farrell exercised stock options and subsequently sold an equal number of shares as part of a pre-arranged 10b5-1 trading plan.

ResMed Director Peter C. Farrell sold 2,000 shares of common stock for $251.31 per share, executed under a pre-arranged 10b5-1 plan.

ResMed's Global General Counsel, Michael J. Rider, executed a pre-scheduled sale of 50 common shares at $260 each on February 4, 2026.

ResMed Inc.'s Chief Financial Officer, Brett Sandercock, sold 1,000 shares of common stock for $257.03 per share as part of a pre-arranged trading plan.

ResMed Inc. Director Peter C. Farrell sold 2,000 shares of common stock for $248.83 per share, executed under a pre-arranged 10b5-1 trading plan.

ResMed Inc.'s Chairman and CEO, Michael J. Farrell, exercised options and sold 4,991 shares of common stock on January 7, 2026, under a pre-arranged 10b5-1 trading plan.

ResMed Inc.'s Chief Financial Officer, Brett Sandercock, sold 1,000 shares of common stock for $241.75 per share as part of a pre-arranged Rule 10b5-1 trading plan.

ResMed's Global General Counsel, Michael J. Rider, sold 50 shares of common stock for $241.75 per share under a pre-arranged 10b5-1 plan.

ResMed Inc. Chairman and CEO Michael J. Farrell sold 4,991 shares of common stock on December 8, 2025, following the exercise of options, under a Rule 10b5-1 plan.

ResMed Director Peter C. Farrell sold 2,000 shares of common stock for $251.47 per share under a pre-arranged 10b5-1 plan.

ResMed Inc.'s Global General Counsel, Michael J. Rider, reported the sale of 50 shares of common stock for $244.16 per share, executed under a pre-arranged Rule 10b5-1 trading plan.

ResMed Inc.'s Chief Financial Officer, Brett Sandercock, sold 1,000 shares of common stock for $244.16 per share on December 1, 2025, under a pre-arranged 10b5-1 trading plan.

ResMed Inc.'s Chairman and CEO, Michael J. Farrell, acquired 33,288 stock options with an exercise price of $250.52.

ResMed Inc. Director Peter C. Farrell acquired 1,331 common stock options with an exercise price of $250.52.

ResMed director Jan De Witte sold 2,055 shares of common stock for $255 per share as part of a pre-arranged Rule 10b5-1 trading plan.

ResMed Inc. director Nicole Mowad-Nassar acquired 1,331 stock options with an exercise price of $250.52, vesting by November 2026.

ResMed's Chief Product Officer, Justin Leong, acquired 1,848 shares of common stock through the vesting of performance-based restricted stock units.

ResMed Director John Hernandez was granted 1,073 Restricted Stock Units, increasing his direct beneficial ownership to 5,118 shares.

ResMed Inc. Director Nicole Mowad-Nassar was awarded 536 Restricted Stock Units, vesting by November 2026.